Hanoi (VNA) – Malaysian authorised agencies hasissued conditional approval for use of the CoronaVac COVID-19 vaccinedeveloped by the Chinese pharmaceutical company Sinovac Biotech as boostershots for those aged 18 and above.
In a recent statement, the Ministry of Health of Malaysiasaid that the Sinovac booster shot will be administered for targeted groupsfrom three to six months after receiving the first two shots.
The approval requires that the information about thequality, safety and effectiveness of the vaccine must be monitored andevaluated regularly based on the latest data available, it said.
Both the finished products of Sinovac vaccines imported fromChina and those manufactured by Malaysian pharmaceutical company Pharmaniagahave been used in the country's national immunisation programme after receivingapproval. Some 78.5 percent of the population have received at least one doseand 76.2 percent are fully vaccinated.
Meanwhile, Indonesian State-run pharmaceutical firm PT BioFarma said that it will launch clinicaltrials of a COVID-19 vaccine to provide booster shots to Indonesian people inearly 2022 with the cooperation with China’s Sinovac.
Bio Farma’s head of service operations Erwin Setiawan saidon November 18 that the trials aims to evaluate the efficiency of the vaccinein stimulating the immune system of human body.
Apart from Sinovac, PT Bio Farma has coordinated with another Chinese firm, Sinopharm,in improving its production capacity.
Erwin said that the Indonesian government is working withthe Development Finance Comptroller (BPKP) to determine the cost of the COVID-19vaccine booster shots. But it can be sure that the vaccine will not be providedfree.
Previously, Indonesia’s Health Ministry said that thebooster vaccine shots will be administered only after more than 50 percent ofthe target recipients are fully vaccinated./.
In a recent statement, the Ministry of Health of Malaysiasaid that the Sinovac booster shot will be administered for targeted groupsfrom three to six months after receiving the first two shots.
The approval requires that the information about thequality, safety and effectiveness of the vaccine must be monitored andevaluated regularly based on the latest data available, it said.
Both the finished products of Sinovac vaccines imported fromChina and those manufactured by Malaysian pharmaceutical company Pharmaniagahave been used in the country's national immunisation programme after receivingapproval. Some 78.5 percent of the population have received at least one doseand 76.2 percent are fully vaccinated.
Meanwhile, Indonesian State-run pharmaceutical firm PT BioFarma said that it will launch clinicaltrials of a COVID-19 vaccine to provide booster shots to Indonesian people inearly 2022 with the cooperation with China’s Sinovac.
Bio Farma’s head of service operations Erwin Setiawan saidon November 18 that the trials aims to evaluate the efficiency of the vaccinein stimulating the immune system of human body.
Apart from Sinovac, PT Bio Farma has coordinated with another Chinese firm, Sinopharm,in improving its production capacity.
Erwin said that the Indonesian government is working withthe Development Finance Comptroller (BPKP) to determine the cost of the COVID-19vaccine booster shots. But it can be sure that the vaccine will not be providedfree.
Previously, Indonesia’s Health Ministry said that thebooster vaccine shots will be administered only after more than 50 percent ofthe target recipients are fully vaccinated./.
VNA
